CFD merupakan instrumen yang rumit dan memiliki risiko tinggi kehilangan uang secara cepat karena adanya pengaruh leverage. 84% akun investor ritel mengalami kerugian saat melakukan kegiatan perdagangan CFD dengan penyedia ini. Anda harus mempertimbangkan apakah Anda memahami cara kerja CFD dan apakah Anda mampu menerima risiko tinggi kehilangan uang.

Scan to Download iOS&Android APP

Perdagangan Cidara Therapeutics, Inc. - CDTX CFD

1.7084
0%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.0732
Biaya inap posisi Long

Long position overnight fee


Margin. Your investment $1,000.00
Biaya Overnight -0.024068 %
Charges from borrowed part ($-0.96)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Kunjungi platform
-0.024068%
Biaya inap posisi short

Short position overnight fee


Margin. Your investment $1,000.00
Biaya Overnight 0.001846 %
Charges from borrowed part ($0.07)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Kunjungi platform
0.001846%
Waktu biaya inap 21:00 (UTC)
Kuantitas min. yang diperdagangkan 1
Mata uang USD
Margin 20%
Bursa efek United States of America
Komisi perdagangan 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 1.7084
Open* 1.7281
1-Year Change* 124.43%
Day's Range* 1.6495 - 1.7379
52 wk Range 0.40-1.99
Average Volume (10 days) 3.96M
Average Volume (3 months) 48.63M
Market Cap 149.82M
P/E Ratio -100.00K
Shares Outstanding 85.13M
Revenue 61.29M
EPS -0.53
Dividend (Yield %) N/A
Beta 1.34
Next Earnings Date Mar 20, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 17, 2023 1.6888 0.0884 5.52% 1.6004 1.7281 1.5709
Mar 16, 2023 1.6004 -0.0490 -2.97% 1.6494 1.6494 1.5709
Mar 15, 2023 1.6495 0.0198 1.21% 1.6297 1.6790 1.6003
Mar 14, 2023 1.6692 0.0199 1.21% 1.6493 1.7183 1.6396
Mar 13, 2023 1.6888 0.1867 12.43% 1.5021 1.7477 1.4432
Mar 10, 2023 1.5219 0.0297 1.99% 1.4922 1.7379 1.4236
Mar 9, 2023 1.4728 -0.1177 -7.40% 1.5905 1.6004 1.4432
Mar 8, 2023 1.5611 -0.1277 -7.56% 1.6888 1.7379 1.5512
Mar 7, 2023 1.6102 0.0590 3.80% 1.5512 1.6888 1.5511
Mar 6, 2023 1.5415 -0.0786 -4.85% 1.6201 1.6495 1.5120
Mar 3, 2023 1.5219 0.0099 0.65% 1.5120 1.5710 1.4039
Mar 2, 2023 1.7674 -0.1374 -7.21% 1.9048 1.9441 1.7182
Mar 1, 2023 1.9343 0.4127 27.12% 1.5216 1.9343 1.5216
Feb 28, 2023 1.4728 0.0985 7.17% 1.3743 1.4924 1.3252
Feb 27, 2023 1.4237 -0.1665 -10.47% 1.5902 1.6201 1.4137
Feb 24, 2023 1.5808 -0.0392 -2.42% 1.6200 1.6299 1.5512
Feb 23, 2023 1.6200 0.0295 1.85% 1.5905 1.6888 1.5807
Feb 22, 2023 1.5611 -0.0193 -1.22% 1.5804 1.6201 1.5316
Feb 21, 2023 1.5709 0.0098 0.63% 1.5611 1.6790 1.5511
Feb 17, 2023 1.5906 0.0394 2.54% 1.5512 1.6102 1.5511

Cidara Therapeutics, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 0 0 0 20.915 12.067 49.572
Cost of Revenue, Total 0
Total Operating Expense 48.436 55.721 63.285 62.639 83.916 91.827
Selling/General/Admin. Expenses, Total 12.737 12.898 14.143 16.238 15.899 18.74
Research & Development 35.699 42.823 49.142 46.401 68.017 73.087
Unusual Expense (Income) 0
Operating Income -48.436 -55.721 -63.285 -41.724 -71.849 -42.255
Interest Income (Expense), Net Non-Operating 0.271 -0.007 4.48 0.632 -0.262 -0.212
Net Income Before Taxes -48.165 -55.728 -59.016 -41.092 -72.111 -42.467
Net Income After Taxes -48.165 -55.728 -59.016 -41.092 -72.111 -42.467
Net Income Before Extra. Items -48.165 -55.728 -59.016 -41.092 -72.111 -42.467
Net Income -48.165 -55.728 -59.016 -41.092 -72.111 -42.467
Income Available to Common Excl. Extra. Items -48.165 -55.728 -69.345 -41.092 -74.873 -42.467
Income Available to Common Incl. Extra. Items -48.165 -55.728 -69.345 -41.092 -74.873 -42.467
Diluted Net Income -48.165 -55.728 -69.345 -41.092 -74.873 -42.467
Diluted Weighted Average Shares 14.489 17.5009 25.143 29.0932 41.5574 52.4534
Diluted EPS Excluding Extraordinary Items -3.32425 -3.1843 -2.75803 -1.41243 -1.80168 -0.80961
Diluted Normalized EPS -3.32425 -3.1843 -2.75803 -1.41243 -1.80168 -0.80961
Total Extraordinary Items 0 0 0
Other, Net -0.211 0
Total Adjustments to Net Income -10.329 0 -2.762 0
Revenue 20.915 12.067 49.572
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 2.408 32.863 7.076 7.225 7.109
Revenue 2.408 32.863 7.076 7.225 7.109
Total Operating Expense 20.63 22.09 25.112 23.995 25.37
Selling/General/Admin. Expenses, Total 4.781 4.37 4.607 4.982 5.204
Research & Development 15.849 17.72 20.505 19.013 20.166
Operating Income -18.222 10.773 -18.036 -16.77 -18.261
Interest Income (Expense), Net Non-Operating -0.07 -0.062 -0.047 -0.033 -0.02
Net Income Before Taxes -18.292 10.711 -18.083 -16.803 -18.281
Net Income After Taxes -18.292 10.711 -18.083 -16.803 -18.281
Net Income Before Extra. Items -18.292 10.711 -18.083 -16.803 -18.281
Net Income -18.292 10.711 -18.083 -16.803 -18.281
Total Adjustments to Net Income 1.892 -1.892 0 0 4.957
Income Available to Common Excl. Extra. Items -16.4 8.819 -18.083 -16.803 -13.324
Income Available to Common Incl. Extra. Items -16.4 8.819 -18.083 -16.803 -13.324
Diluted Net Income -16.4 8.819 -18.083 -16.803 -13.324
Diluted Weighted Average Shares 48.2519 59.3232 49.534 64.6075 68.1381
Diluted EPS Excluding Extraordinary Items -0.33988 0.14866 -0.36506 -0.26008 -0.19554
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.33988 0.14866 -0.36506 -0.26008 -0.19554
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 105.398 77.67 77.129 65.814 57.191 71.698
Cash and Short Term Investments 104.619 75.314 74.562 50.268 35.912 59.68
Cash & Equivalents 85.367 60.813 74.562 50.268 35.912 59.68
Short Term Investments 19.252 14.501 0
Prepaid Expenses 0.779 2.035 2.567 3.067 4.069
Total Assets 106.962 79.035 79.112 68.976 60.424 75.325
Property/Plant/Equipment, Total - Net 1.374 1.044 0.712 2.061 1.21 2.543
Property/Plant/Equipment, Total - Gross 2.744 3.064 3.255 4.903 4.262 5.767
Accumulated Depreciation, Total -1.37 -2.02 -2.543 -2.842 -3.052 -3.224
Other Long Term Assets, Total 0.19 0.321 1.271 1.101 2.023 1.084
Total Current Liabilities 8.909 12.085 19.892 30.199 38.564 34.017
Accounts Payable 2.909 2.59 2.846 1.887 4.568 1.301
Accrued Expenses 6 6.828 6.707 8.544 13.108 16.205
Notes Payable/Short Term Debt 0 0 0 0 0 0
Total Liabilities 18.783 19.291 19.973 31.141 49.709 53.752
Total Long Term Debt 9.794 7.206 0 0 0 0
Long Term Debt 9.794 7.206 0 0
Other Liabilities, Total 0.08 0 0.081 0.942 11.145 19.735
Total Equity 88.179 59.744 59.139 37.835 10.715 21.573
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.002 0.002 0.003 0.003 0.004 0.007
Additional Paid-In Capital 181.84 209.14 277.871 297.659 345.411 398.733
Retained Earnings (Accumulated Deficit) -93.662 -149.39 -218.735 -259.827 -334.7 -377.167
Other Equity, Total -0.001 -0.008 0
Total Liabilities & Shareholders’ Equity 106.962 79.035 79.112 68.976 60.424 75.325
Total Common Shares Outstanding 16.7713 20.5257 27.816 33.8385 44.8764 67.8637
Total Receivables, Net 0.321 0 5.546 11.175 5.356
Accounts Receivable - Trade, Net 0.321 0 5.546 11.175 5.356
Current Port. of LT Debt/Capital Leases 2.667 9.928 9.965 7.023 2.591
Other Current Liabilities, Total 0.411 9.803 13.865 13.92
Other Current Assets, Total 10 7.037 2.593
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 51.301 61.076 47.276 71.698 52.007
Cash and Short Term Investments 42.863 48.284 36.601 59.68 36.488
Cash & Equivalents 42.863 48.284 36.601 59.68 36.488
Total Receivables, Net 0.011 3.157 3.872 5.356 8.783
Accounts Receivable - Trade, Net 0.011 3.157 3.872 5.356 8.783
Prepaid Expenses 2.501 4.82 3.099 4.069 5.254
Other Current Assets, Total 5.926 4.815 3.704 2.593 1.482
Total Assets 54.21 63.744 51.206 75.325 55.295
Property/Plant/Equipment, Total - Net 0.948 0.707 2.756 2.543 2.269
Other Long Term Assets, Total 1.961 1.961 1.174 1.084 1.019
Total Current Liabilities 39.966 33.887 33.49 34.017 32.105
Accounts Payable 3.215 2.587 3.242 1.301 2.861
Accrued Expenses 15.424 12.031 13.518 16.205 13.503
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 5.916 4.808 3.7 2.591 1.481
Other Current Liabilities, Total 15.411 14.461 13.03 13.92 14.26
Total Liabilities 52.318 47.955 52.364 53.752 50.338
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 12.352 14.068 18.874 19.735 18.233
Total Equity 1.892 15.789 -1.158 21.573 4.957
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.005 0.005 0.005 0.007 0.007
Additional Paid-In Capital 354.879 358.065 359.201 398.733 400.398
Retained Earnings (Accumulated Deficit) -352.992 -342.281 -360.364 -377.167 -395.448
Total Liabilities & Shareholders’ Equity 54.21 63.744 51.206 75.325 55.295
Total Common Shares Outstanding 48.2887 49.5063 49.6215 67.8637 69.0492
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -48.165 -55.728 -59.016 -41.092 -72.111 -42.467
Cash From Operating Activities -39.771 -49.909 -56.705 -28.532 -54.411 -25.232
Cash From Operating Activities 0.732 0.667 0.523 0.328 0.286 0.189
Non-Cash Items 4.182 5.731 2.187 4.745 4.054 2.61
Changes in Working Capital 3.48 -0.579 -0.399 7.487 13.36 14.436
Cash From Investing Activities 25.482 4.471 14.301 -0.035 -0.186 -0.041
Capital Expenditures -0.401 -0.306 -0.177 -0.035 -0.186 -0.041
Other Investing Cash Flow Items, Total 25.883 4.777 14.478 0 0
Cash From Financing Activities 37.094 20.884 56.153 14.273 37.278 44.597
Financing Cash Flow Items 26.622 -0.031 0 0
Issuance (Retirement) of Stock, Net 0.525 20.884 56.153 14.304 40.241 49.041
Issuance (Retirement) of Debt, Net 9.947 0 0 -2.963 -4.444
Net Change in Cash 22.805 -24.554 13.749 -14.294 -17.319 19.324
Cash Interest Paid 0.511 0.582 0.616 0.445 0.228
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -18.292 -7.581 -25.664 -42.467 -18.281
Cash From Operating Activities -1.793 1.647 -10.325 -25.232 -23.608
Cash From Operating Activities 0.057 0.107 0.152 0.189 0.039
Non-Cash Items 0.866 1.727 2.702 2.61 1.597
Cash Interest Paid 0.075 0.139 0.19 0.228 0.025
Changes in Working Capital 15.576 7.394 12.485 14.436 -6.963
Cash From Investing Activities -0.012 -0.029 -0.041 -0.041 -0.084
Capital Expenditures -0.012 -0.029 -0.041 -0.041 -0.084
Cash From Financing Activities 7.645 8.532 7.722 44.597 -0.611
Issuance (Retirement) of Stock, Net 8.756 10.754 11.055 49.041 0.5
Issuance (Retirement) of Debt, Net -1.111 -2.222 -3.333 -4.444 -1.111
Net Change in Cash 5.84 10.15 -2.644 19.324 -24.303
Financing Cash Flow Items 0
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
BVF Partners L.P. Hedge Fund 8.0599 6861127 0 2022-12-31 LOW
Mundipharma AG Corporation 5.6168 4781408 0 2022-09-30 LOW
Nantahala Capital Management, LLC Hedge Fund 5.1305 4367464 -191737 2022-12-31 MED
Point72 Asset Management, L.P. Hedge Fund 4.5438 3868006 0 2022-12-31 HIGH
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.9005 2469150 1217 2022-12-31 LOW
Medical Strategy GmbH Investment Advisor 2.0598 1753431 290000 2022-09-30 LOW
Lytton (Laurence W) Individual Investor 2.0068 1708328 -1632072 2021-12-31 MED
Alethea Capital Management, LLC Investment Advisor 1.9702 1677194 0 2022-12-31 MED
Acadian Asset Management LLC Investment Advisor/Hedge Fund 1.4761 1256602 43071 2022-12-31 MED
Renaissance Technologies LLC Hedge Fund 1.3925 1185373 -107900 2022-12-31 HIGH
5AM Ventures Venture Capital 1.3327 1134511 0 2022-12-31 LOW
Stein (Jeffrey L Ph.D.) Individual Investor 1.2161 1035246 4000 2022-09-30 LOW
Millennium Management LLC Hedge Fund 0.8105 689917 606201 2022-12-31 HIGH
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.6963 592724 7743 2022-12-31 LOW
West Family Investments, Inc. Investment Advisor 0.4334 368910 0 2022-12-31 LOW
Citadel Advisors LLC Hedge Fund 0.3543 301612 301612 2022-12-31 HIGH
Callan Capital, LLC Investment Advisor 0.3213 273554 273554 2022-12-31 LOW
U.S. Bancorp Asset Management, Inc. Investment Advisor 0.3079 262072 0 2022-12-31 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.2713 230937 0 2022-12-31 LOW
Invus Public Equities Advisors, LLC Investment Advisor 0.2639 224675 0 2022-12-31 LOW

Mengapa memilih Capital.com? Biarlah angka kami yang berbicara.

Capital.com Group
500000+

Trader

92000+

Klien aktif per bulan

$53000000+

Volume investasi per bulan

$30000000+

Penarikan tiap bulan

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long
Industry: Bio Therapeutic Drugs

6310 Nancy Ridge Dr Ste 101
SAN DIEGO
CALIFORNIA 92121-3209
US

Income Statement

  • Annual
  • Quarterly

People also watch

Oil - Crude

66.64 Price
+0.200% 1D Chg, %
Biaya inap posisi Long -0.0200%
Biaya inap posisi short -0.0019%
Waktu biaya inap 21:00 (UTC)
Spread 0.03

US100

12,547.10 Price
+0.240% 1D Chg, %
Biaya inap posisi Long -0.0241%
Biaya inap posisi short 0.0018%
Waktu biaya inap 21:00 (UTC)
Spread 1.8

BTC/USD

27,983.90 Price
+0.020% 1D Chg, %
Biaya inap posisi Long -0.0616%
Biaya inap posisi short 0.0137%
Waktu biaya inap 21:00 (UTC)
Spread 60.00

XRP/USD

0.38 Price
-1.810% 1D Chg, %
Biaya inap posisi Long -0.0753%
Biaya inap posisi short 0.0069%
Waktu biaya inap 21:00 (UTC)
Spread 0.00328

Masih mencari broker yang bisa Anda percayai?

Bergabung dengan 500.000+ trader di seluruh dunia yang telah memilih trading bersama Capital.com

1. Buat & verifikasi akun Anda 2. Lakukan deposit 3. Temukan trading Anda